Drugs / LUT014
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03876106 | Aug 2019 → Jul 2020 | acneiform dermatitis | Lutris Pharma Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04261387 | Jan 2021 → Jun 2022 | radiodermatitis | Lutris Pharma Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04759664 | Apr 2021 → Mar 2024 | acneiform dermatitis | Lutris Pharma Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUT014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261387 ↗ |
| Modality | Small molecule | — CHEMBL5095249 ↗ |
| Route | Topical | “will be topically applied” NCT03876106 ↗ |